So therefore, the collection of the cells could be something that takes two to three months or even longer in some circumstances. And therefore, we hope and we think that we may be able to show better mobilization and perhaps even reduce the number of mobilization cycles to a bare minimum and therefore, save a significant amount of time and discomfort for the sickle cell patients since that’s the idea behind our value proposition there.
Holly May: There’s one other thing that you were speaking that I thought I would add on that is very unique about these approaches to gene therapy that you mentioned, in particular, John, the Vertex product. And that is the manufacturing and the manufacturing of the cells that go into that. That’s one — another reason why a very high number of CD34+ themselves are required for these types of therapies just because there’s always the need for backup in case something this is personalized medicine and gene therapy, obviously, that is manufactured for the individual. And so there is always a need for back up through the manufacturing processes, which just, again, drives the need for a very, very high number of stem cells.
John Vandermosten: Okay. Great. Yeah. It will be exciting to see how this turns out with that product and maybe you guys will be involved. A couple of questions on — there’s been a lot of, I guess, cash flow movements and share movements recently. And I’m wondering if you can give me some kind of sense of where cash and share balance might be at the beginning of the — at the end of the year, beginning of the year, December 31. Can you help me with that?
Phil Serlin: Yes. So I mean, I think we discussed our cash. We including the almost $30 million that we received from the deals or the agreements, the license and the equity investment. We have in excess of $50 million in cash on a pro forma basis, which, as we mentioned, is enough to take us into 2025. We also, as Molly mentioned, we have a $30 million debt facility that’s available to us. And so we feel quite comfortable from a cash perspective that we can meet everything that we need to do from a launch perspective in the near future. from that. So as a — you also asked about the number of shares, is that what you asked? Do you want to?
John Vandermosten: Yes, yes, exactly.
Phil Serlin: I think what Molly. No, but in ADS, I think we have about 70. We have somewhere — the exact number is in front of me. I apologize. I think it’s somewhere around 70 million (ph) outstanding ADSs.
John Vandermosten: Okay. Great. And then last one for me is just any kind of revenue guidance that you can provide us for the fourth quarter?
Phil Serlin: Yes. I mean that’s the question. So listen, John, I mean, we’re happy, as Holly mentioned, we’re happy with the way things are progressing. And there’s a lot of activity that we’re doing on all fronts, hospitals KOLs. The committees, P&T committees, as you know, we also got on the NCCN guidelines, et cetera. But as I’m sure you’re aware, we can’t, of course, get into sales forecast and companies usually don’t give forecast on commercial launches. And so that’s about all we can say at this point.
John Vandermosten: Right. I mean, lots of [indiscernible] there. Well thank you. You guys are in a great place and I appreciate you taking my questions.
Phil Serlin: Thanks so much.
Operator: This concludes the question-and-answer session. Before I ask Mr. Phil Serlin to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin 2 hours after the conference. In the U.S. please call 1 (888) 295-2634. In Israel, please call (03) 925-5904. Internationally, please call 9723-9255-904. Mr. Serlin, would you like to make your concluding statements?
Phil Serlin: Yes. Thank you, operator. In closing, we are progressing through 2023 with significant momentum. We are launching our first therapy in stem cell mobilization and are making significant progress, raising awareness of the many benefits APHEXDA can bring to payers and transplant centers. We completed our first ex-U.S. partnership agreement for APHEXDA and are evaluating the potential of commercial partnerships in other significant markets. We have made important additional life cycle management steps through both our PDAC program as well as our program for stem cell mobilization for gene therapies. I am very pleased with our progress during the third quarter, and I’m excited about what we are in the process of achieving. Thank you all very much for your continued interest in BioLineRx. We look forward to providing our next comprehensive quarterly update in March. Be safe, and have a great day.
Operator: Thank you. This concludes the BioLineRx third quarter 2023 conference call. Thank you for your participation. You may go ahead and disconnect.
